Chlorophyll As A Toxin Binder
Chlorophyll And Chlorophyllin Used As Mycotoxin Binders
Chlorophyllin (Semisenthetic derivative of chlorophyll)
Cancer Prev Res (Phila). 2009 Dec;2(12):1015-22. doi: 10.1158/1940-6207.CAPR-09-0099. Epub 2009 Dec 1.
Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B(1) pharmacokinetics in human volunteers.
Jubert C1, Mata J, Bench G, Dashwood R, Pereira C, Tracewell W, Turteltaub K, Williams D, Bailey G.
Chlorophyll (Chla) and chlorophyllin (CHL) were shown previously to reduce carcinogen bioavailability, biomarker damage, and tumorigenicity in trout and rats. These findings were partially extended to humans, where CHL reduced excretion of aflatoxin B(1) (AFB(1))-DNA repair products in Chinese unavoidably exposed to dietary AFB(1). However, neither AFB(1) pharmacokinetics nor Chla effects were examined. We conducted an unblinded crossover study to establish AFB(1) pharmacokinetic parameters among four human volunteers, and to explore possible effects of CHL or Chla cotreatment in three of those volunteers. For protocol 1, fasted subjects received an Institutional Review Board-approved dose of 14C-AFB(1) (30 ng, 5 nCi) by capsule with 100 mL water, followed by normal eating and drinking after 2 hours. Blood and cumulative urine samples were collected over 72 hours, and 14C- AFB(1) equivalents were determined by accelerator mass spectrometry. Protocols 2 and 3 were similar except capsules also contained 150 mg of purified Chla or CHL, respectively. Protocols were repeated thrice for each volunteer. The study revealed rapid human AFB(1) uptake (plasma k(a), 5.05 + or - 1.10 h(-1); T(max), 1.0 hour) and urinary elimination (95% complete by 24 hours) kinetics. Chla and CHL treatment each significantly impeded AFB(1) absorption and reduced Cmax and AUCs (plasma and urine) in one or more subjects. These initial results provide AFB(1) pharmacokinetic parameters previously unavailable for humans, and suggest that Chla or CHL co-consumption may limit the bioavailability of ingested aflatoxin in humans, as they do in animal models.
PMID: 19952359 [PubMed - indexed for MEDLINE] Free full text
Chlorophyllin (a mixture of semisynthetic, water-soluble derivatives of chlorophyll) reduces aflatoxin. Chlorophyllin consumption at each meal led to an overall 55% reduction (P = 0.036) in median urinary levels of this aflatoxin biomarker (aflatoxin-N7-guanine adducts in urine) compared with those taking placebo.
Chlorophyllin is a chlorophyll derivative that inhibits CYP activity, and stimulates GST activity in cell culture and rodent models. So, it can enance removal of mycotoxins via glutathione conjugation as well as binding them in the gut.
The unique chemical structures of chlorophyllin and chlorophyll enable them to bind toxins in the gut preventing their absorption. In animal models, chlorophyllin and chlorophyll lower the bioavailability and accelerate the excretion of several environmental carcinogens. Mycotoxin trapping may partly explain the results of a human trial of residents of Qidong, China, an area with a high incidence of liver cancer due to exposure to aflatoxin (a toxin produced by species of the fungus Aspergillus). Among 180 people who took 100 mg of chlorophyllin three times daily, urinary levels of DNA-aflatoxin conjugates (a marker for DNA mutation) went down 55% compared to untreated people.
Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci 2001;98(25): 14601 - 6 Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, et al.
Remember To Send This To Friends And Family Who Will Benefit From Reading It!